Dr. Okorie is board certified in pediatric pulmonology, sleep medicine and general pediatrics and joined the Division of Pediatric Pulmonary, Asthma and Sleep Medicine in 2018. She obtained her medical degree and Master’s in Public Health at the University of Arizona before going on to a residency and chief residency in pediatrics at Oregon Health & Science University. She completed her fellowship training in both pediatric pulmonary medicine and sleep medicine at Stanford University. She has a passion for medical education and serves as an Associate Program Director for the Pediatric Residency Program at Stanford.
She treats children with a variety of lung diseases, including: asthma, chronic cough, cystic fibrosis, chronic respiratory failure, and chronic lung disease of prematurity. Her additional training in sleep medicine allows her expertise to treat sleep disorders, including: sleep disordered breathing, parasomnias, narcolepsy, restless legs syndrome, and insomnia.
- Pediatric Pulmonary
- Sleep Medicine
- Insomnia Disorders
- Sleep Related Movement Disorders
- Sleep Disordered Breathing
Clinical Assistant Professor, Pediatrics - Pulmonary Medicine
Associate Program Director, Stanford Pediatrics Residency Program, Stanford School of Medicine, Department of Pediatrics (2019 - Present)
Faculty Coach, Stanford Pediatrics Residency Program, Stanford School of Medicine, Department of Pediatrics (2018 - 2020)
Boards, Advisory Committees, Professional Organizations
Member, American College of Chest Physicians, Sleep Networks Committee (2019 - Present)
Member, American Thoracic Society Education Committee (2019 - Present)
Board Certification: American Board of Pediatrics, Sleep Medicine (2019)
Board Certification, American Board of Pediatrics, Pediatric Pulmonary Medicine (2018)
Board Certification, American Board of Pediatrics, Pediatrics (2013)
Fellowship, Stanford University, Department of Psychiatry, Sleep Medicine (2018)
Fellowship, Stanford University, Department of Pediatrics, Pediatric Pulmonary Medicine (2017)
Chief Residency, Oregon Health & Science University, Pediatrics (2014)
Residency, Oregon Health & Science University, Pediatrics (2013)
MD, University of Arizona College of Medicine, Medicine (2010)
MPH, Mel and Enid Zuckerman College of Public Health, Public Health (2010)
BA, Stanford University, English Literature (2003)
ATS Core Curriculum 2020. Pediatric Pulmonary Medicine.
2020; 1 (4): 456–75
The American Thoracic Society Core Curriculum updates clinicians annually in adult and pediatric pulmonary disease, medical critical care, and sleep medicine, in a 3- to 4-year recurring cycle of topics. These topics will be presented at the 2020 International Conference. Below is the pediatric pulmonary medicine core, including pediatric hypoxemic respiratory failure; modalities in noninvasive management of chronic respiratory failure in childhood; surgical and nonsurgical management of congenital lung malformations; an update on smoke inhalation lung injury; an update on vaporizers, e-cigarettes, and other electronic delivery systems; pulmonary complications of sarcoidosis; pulmonary complications of congenital heart disease; and updates on the management of congenital diaphragmatic hernia.
View details for DOI 10.34197/ats-scholar.2020-0022RE
View details for PubMedID 33870313
- The nocturnal-polysomnogram and "non-hypoxic sleep-disordered-breathing" in children SLEEP MEDICINE 2019; 60: 31–44
- Sleep The Handbook of Personal Health and Wellbeing for Physicians and Trainees edited by Weiss Roberts, L., Trockel, M. Springer International Publishing. 2019
The nocturnal-polysomnogram and "non-hypoxic sleep-disordered-breathing" in children.
OBJECTIVE: To characterize sleep-disordered breathing patterns not related to hypoxia resulting in fragmented sleep in children.METHODS: We reviewed the polysomnogram (PSG) data of children with sleep complaints who were being evaluated for sleep-disordered breathing and had an apnea-hypopnea-index≤3. These data were compared to the recordings of the same children with nasal CPAP administered for one night and to 60 control subjects (children without any sleep complaints). A subgroup of children was monitored with esophageal manometry, but nasal cannula flow data was recorded in all cases.RESULTS: Abnormal breathing patterns, particularly flow limitation, could be seen with more severity and frequency compared to apnea or hypopnea. The observed abnormal breathing patterns were associated with EEG disturbances.CONCLUSIONS: Patterns such as flow-limitation, mouth-breathing, changes in inspiratory and expiratory time, rib-cage and expiratory muscle activity, transcutaneous CO2 electrode changes and snoring noises are all variables that should be systematically reviewed when analyzing nocturnal PSG. Current scoring guidelines emphasizes apnea-hypopnea and hypoxic-sleep disordered breathing and therefore treatment is often much delayed in this population of children with evidence of abnormal breathing patterns. Analysis of the various patterns of abnormal breathing noted above allows recognition of "non-hypoxic" sleep-disordered-breathing (SDB).
View details for PubMedID 30578113
Diagnosis And Management Of Sporadic Pulmonary Arteriovenous Malformation Not Associated With Hereditary Hemorrhagic Telangiectasia
AMER THORACIC SOC. 2016
View details for Web of Science ID 000390749605287
Allergic Bronchopulmonary Aspergillosis.
Journal of fungi (Basel, Switzerland)
2016; 2 (2)
Allergic bronchopulmonary aspergillosis (ABPA), a progressive fungal allergic lung disease, is a common complication of asthma or cystic fibrosis. Although ABPA has been recognized since the 1950s, recent research has underscored the importance of Th2 immune deviation and granulocyte activation in its pathogenesis. There is also strong evidence of widespread under-diagnosis due to the complexity and lack of standardization of diagnostic criteria. Treatment has long focused on downregulation of the inflammatory response with prolonged courses of oral glucocorticosteroids, but more recently concerns with steroid toxicity and availability of new treatment modalities has led to trials of oral azoles, inhaled amphotericin, pulse intravenous steroids, and subcutaneously-injected anti-IgE monoclonal antibody omalizumab, all of which show evidence of efficacy and reduced toxicity.
View details for PubMedID 29376934
A Presentation Of Hepatopulmonary Syndrome In A Five Year Old During Evaluation For Miliary Tuberculosis
AMER THORACIC SOC. 2015
View details for Web of Science ID 000377582808172
Successful Treatment Of Mineral Oil Associated Lipoid Pneumonia In An Infant
AMER THORACIC SOC. 2013
View details for Web of Science ID 000209839101412